Acquisition History / Merck KGaA / Bio-Techne Corporation
Merck KGaA Acquires Bio-Techne Corporation
Announced June 2026 — $11.30B
What happened
Bio-Techne is a US life-science tools and reagents company. German science and technology group Merck KGaA agreed to acquire it for US$73 per share in cash, an enterprise value of about US$11.3B, with completion expected late 2026 or early 2027 subject to approvals.
- Acquirer
- Merck KGaA
- Target
- Bio-Techne Corporation
- Announced
- June 2026
- Price
- $11.30B
- Industry
- Life science tools and reagents
- Buyer type
- Strategic acquirer
- Status
- Announced, not yet closed
By the numbers
Frequently Asked Questions About This Acquisition
When did Merck KGaA acquire Bio-Techne Corporation?
Merck KGaA acquired Bio-Techne Corporation on June 2026. This was Merck KGaA's 1st publicly tracked acquisition out of 1 we have on record.
How much did Merck KGaA pay for Bio-Techne Corporation?
Merck KGaA paid $11.30B for Bio-Techne Corporation.
What does Bio-Techne Corporation do?
Bio-Techne is a US life-science tools and reagents company. German science and technology group Merck KGaA agreed to acquire it for US$73 per share in cash, an enterprise value of about US$11.3B, with completion expected late 2026 or early 2027 subject to approvals.
What other Life science tools and reagents companies has Merck KGaA acquired?
Bio-Techne Corporation is Merck KGaA's only publicly tracked acquisition in Life science tools and reagents so far.